Pryor Medical Devices has received U.S. Food and Drug Administration (FDA) approval for the sale and distribution of its ER-REBOA catheter.
REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) is a minimally invasive technique used by the trauma, critical care and emergency medicine community to temporarily occlude large vessels using a balloon.
‘Features of ER-REBOA include its small 7 french scale size, which precludes the need for extra surgical repair at the access site. The catheter doesn''t require multiple wire exchanges. It also has a soft, atraumatic tip and offers simultaneous arterial pressure monitoring.’
Advertisement"We are proud to be the first to market with a balloon occlusion catheter designed specifically for this community. They asked for the unique combination of features found on the ER-REBOA catheter, and we look forward to getting it to them," said David A. Spencer, CEO of Pryor Medical Devices.
Features of ER-REBOA include its small 7 French scale size, which precludes the need for extra surgical repair at the access site. The catheter doesn't require multiple wire exchanges. Most importantly, it also has a soft, atraumatic tip and offers simultaneous arterial pressure monitoring.
The medical device company has scheduled first delivery of its catheters for January 1, 2016.
POne More Feather on Its Cap! Smartphones Turn into Air Pollution Detectors! 51% Stakes of Delhi-Based Saket City Hospital to be Acquired by Max Healthcare M
You May Also Like